Boehringer Ingelheim Corporation To Present Highly Anticipated Phase III Data In IPF And COPD At American Thoracic Society International Conference

Published: Apr 30, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

For media outside UK, U.S. and Canada

Boehringer Ingelheim announced today that the first results of the two confirmatory Phase III INPULSISTM trials, investigating nintedanib* in the treatment of idiopathic pulmonary fibrosis (IPF), will be presented at the 2014 American Thoracic Society (ATS) International Conference taking place 16 – 21 May in San Diego. IPF is a rare, debilitating and fatal lung disease for which treatment options are limited.

Help employers find you! Check out all the jobs and post your resume.

Back to news